CDKN2B

Protein identityUniProt · HPA

UniProt accession

P42772

Gene

CDKN2B

Ensembl

ENSG00000147883

Chromosome

9

Canonical length

138 aa

Protein class

Human disease related genes, Predicted intracellular proteins

Subcellular location

Nucleoplasm,Cytosol

OverviewNCBI Gene

This gene lies adjacent to the tumor suppressor gene CDKN2A in a region that is frequently mutated and deleted in a wide variety of tumors. This gene encodes a cyclin-dependent kinase inhibitor, which forms a complex with CDK4 or CDK6, and prevents the activation of the CDK kinases, thus the encoded protein functions as a cell growth regulator that controls cell cycle G1 progression. The expression of this gene was found to be dramatically induced by TGF beta, which suggested its role in the TGF beta induced growth inhibition. Two alternatively spliced transcript variants of this gene, which encode distinct proteins, have been reported. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

138 residues, UniProt reviewed canonical sequence.

>P42772|CDKN2B
     1  MREENKGMPS GGGSDEGLAS AAARGLVEKV RQLLEAGADP NGVNRFGRRA IQVMMMGSAR
    61  VAELLLLHGA EPNCADPATL TRPVHDAARE GFLDTLVVLH RAGARLDVRD AWGRLPVDLA
   121  EERGHRDVAG YLRTATGD

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CDKN2B can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability

Intracellular

Secreted

No

Transmembrane segments

0

Mean surface accessibility (rSASA)

0.3

Highest tissue expression

37 nTPM

Expression across tissuesHPA

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about CDKN2B.

Disease | GeneticClinVar

4 pathogenic / likely-pathogenic of 50 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

• Malignant tumor of breast

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)

1.83

gnomAD pLI

0.01

gnomAD missense Z

-0.7

DepMap mean gene effect

0.07

DepMap dependency class

selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

• cellular response to cell-matrix adhesion
• cellular response to nutrient
• cellular senescence
• megakaryocyte differentiation
• negative regulation of cell population proliferation
• negative regulation of epithelial cell proliferation
• negative regulation of G1/S transition of mitotic cell cycle
• positive regulation of transforming growth factor beta receptor signaling pathway
• regulation of G0 to G1 transition
• regulation of G1/S transition of mitotic cell cycle
• spleen development
• transforming growth factor beta receptor signaling pathway

Molecular functions

• cyclin-dependent protein serine/threonine kinase inhibitor activity
• protein kinase binding

Cellular components

• cytoplasm
• cytosol
• nucleus

Protein domainsUniProt · Pfam · InterPro

• Ankyrin repeat
• Ankyrin repeat-containing domain superfamily
• Ankyrin Repeat and Cyclin-Dependent Kinase Inhibitor
• Ankyrin repeats (3 copies)

KeywordsUniProt

• ANK repeat
• Cell cycle
• Cytoplasm
• Repeat
• Tumor suppressor

InteractionsUniProt · HPA

Protein binding partners of CDKN2B in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

• CDK4
• CDK6
• PYCR3